Advertisement

Rheumatology International

, Volume 35, Issue 3, pp 471–477 | Cite as

Serum IL-33 level and IL-33 gene polymorphisms in Behçet’s disease

  • Suleyman Serdar KocaEmail author
  • Murat Kara
  • Firat Deniz
  • Metin Ozgen
  • Caner Feyzi Demir
  • Nevin Ilhan
  • Ahmet Isik
Original Article - Genes and Disease

Abstract

Behçet’s disease (BD) is a chronic inflammatory disease. Increased productions of cytokines including interleukin (IL)-1β and IL-18 are documented, and IL-1α and β gene polymorphisms are associated with susceptibility to the disease. IL-33 is a recently discovered member of IL-1 cytokine family. The aim of the study was to detect serum IL-33 level and IL-33 gene polymorphisms in a cohort of BD. Unrelated 117 patients with BD and 149 healthy controls (HC) were enrolled. Serum IL-33 levels were analyzed by enzyme-linked immunosorbent assay method. DNA samples were harvested using an appropriate commercial DNA isolation kit. Four single nucleotide polymorphisms of IL-33 gene (rs7044343, rs1157505, rs11792633 and rs1929992) were genotyped using the appropriate commercial primer/probe sets on real-time PCR. Serum IL-33 level was not significantly different in the BD and HC groups (p > 0.05). However, its level was lower in the active BD patients compared to the inactive ones and HC group (p = 0.044 and p = 0.037, respectively). There was no significant difference in terms of the genotypic and allelic distributions of rs1157505 and rs1929992 polymorphisms (p > 0.05 for all). However, the TT variants of rs7044343 and rs11792633 polymorphisms were very rare, and the T allele frequencies of these polymorphisms were lower, in the BD group compared to the HC group (p < 0.0001 for all). The rs7044343 and rs11792633 variants of IL-33 gene are associated with the decreased risk of BD in our cohort. Therefore, it may be concluded that IL-33 acts a protective role on the pathogenesis of BD.

Keywords

Behçet’s disease IL-33 Polymorphisms 

Notes

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Verity DH, Marr JE, Ohno S, Wallace GR, Stanford MR (1999) Behçet’s disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens 54(3):213–220CrossRefPubMedGoogle Scholar
  2. 2.
    Pineton de Chambrun M, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev 11(10):687–698CrossRefPubMedGoogle Scholar
  3. 3.
    Zhou ZY, Chen SL, Shen N, Lu Y (2012) Cytokines and Behcet’s disease. Autoimmun Rev 11(10):699–704CrossRefPubMedGoogle Scholar
  4. 4.
    Schmitz J, Owyang A, Oldham E et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490CrossRefPubMedGoogle Scholar
  5. 5.
    Talabot-Ayer D, McKee T, Gindre P, Bas S, Baeten DL, Gabay C, Palmer G (2012) Distinct serum and synovial fluid interleukin (IL)-33 levels in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. Joint Bone Spine 79(1):32–37CrossRefPubMedGoogle Scholar
  6. 6.
    Matsuyama Y, Okazaki H, Tamemoto H et al (2010) Increased levels of interleukin 33 in sera and synovial fluid from patients with active rheumatoid arthritis. J Rheumatol 37(1):18–25CrossRefPubMedGoogle Scholar
  7. 7.
    Hamzaoui K, Kaabachi W, Fazaa B, Zakraoui L, Mili Boussen I, Haj Sassi F (2013) Serum IL-33 levels and skin mRNA expression in Behçet’s Disease. Clin Exp Rheumatol 31(3 Suppl 77):6–14PubMedGoogle Scholar
  8. 8.
    Manetti M, Guiducci S, Ceccarelli C et al (2011) Increased circulating levels of interleukin 33 in systemic sclerosis correlate with early disease stage and microvascular involvement. Ann Rheum Dis 70(10):1876–1878CrossRefPubMedGoogle Scholar
  9. 9.
    Yang Z, Liang Y, Xi W, Li C, Zhong R (2011) Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population. Clin Exp Med. 11(2):75–80CrossRefPubMedGoogle Scholar
  10. 10.
    Wu H, Romieu I, Shi M et al (2010) Evaluation of candidate genes in a genome-wide association study of childhood asthma in Mexicans. J Allergy Clin Immunol 125(2):321–327CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Buysschaert ID, Grulois V, Eloy P, Jorissen M, Rombaux P, Bertrand B, Collet S, Bobic S, Vlaminck S, Hellings PW, Lambrechts D (2010) Genetic evidence for a role of IL33 in nasal polyposis. Allergy 65(5):616–622CrossRefPubMedGoogle Scholar
  12. 12.
    Latiano A, Palmieri O, Pastorelli L et al (2013) Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS ONE 8(4):e62144CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Chapuis J, Hot D, Hansmannel F et al (2009) Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer’s disease. Mol Psychiatry 14:1004–1016CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Yu JT, Song JH, Wang ND et al (2012) Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer’s disease. Neurobiol Aging 33(5):1014.e11–1014.e14CrossRefGoogle Scholar
  15. 15.
    The International Study Group for Behcet’s disease (1990) Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet 335(8697):1078–1080Google Scholar
  16. 16.
    Shi YY, He L (2005) SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 15(2):97–98CrossRefPubMedGoogle Scholar
  17. 17.
    Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H (2004) Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum 50(7):2291–2295CrossRefPubMedGoogle Scholar
  18. 18.
    Raziuddin S, Al-Dalaan A, Bahabri S, Siraj AK, Al-Sedairy S (1998) Divergent cytokine production profile in Behçet’s disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol 25(2):329–333PubMedGoogle Scholar
  19. 19.
    Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K (2002) Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol 31(4):205–210CrossRefPubMedGoogle Scholar
  20. 20.
    Pay S, Erdem H, Pekel A, Simsek I, Musabak U, Sengul A, Dinc A (2006) Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet’s disease. Does interleukin-1beta play a major role in Behçet’s synovitis? Rheumatol Int 26(7):608–613CrossRefPubMedGoogle Scholar
  21. 21.
    Ertenli I, Kiraz S, Calgüneri M, Celik I, Erman M, Haznedaroglu IC, Kirazli S (2001) Synovial fluid cytokine levels in Behçet’s disease. Clin Exp Rheumatol 19(5 Suppl 24):S37–S41PubMedGoogle Scholar
  22. 22.
    Akman A, Ekinci NC, Kacaroglu H, Yavuzer U, Alpsoy E, Yegin O (2008) Relationship between periodontal findings and specific polymorphisms of interleukin-1alpha and-1beta in Turkish patients with Behçet’s disease. Arch Dermatol Res 300(1):19–26CrossRefPubMedGoogle Scholar
  23. 23.
    Alayli G, Aydin F, Coban AY et al (2007) T helper 1 type cytokines polymorphisms: association with susceptibility to Behçet’s disease. Clin Rheumatol 26(8):1299–1305CrossRefPubMedGoogle Scholar
  24. 24.
    Oboki K, Ohno T, Kajiwara N, Saito H, Nakae S (2010) IL-33 and IL-33 receptors in host defense and diseases. Allergol Int 59:143–160CrossRefPubMedGoogle Scholar
  25. 25.
    Li XL, Lin TT, Qi CY, Yuan L, Xia LP, Shen H, Lu J (2013) Elevated serum level of IL-33 and sST2 in patients with ankylosing spondylitis: associated with disease activity and vascular endothelial growth factor. J Investig Med 61(5):848–851PubMedGoogle Scholar
  26. 26.
    Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J (2013) Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 31(3):428–432PubMedGoogle Scholar
  27. 27.
    Mok MY, Huang FP, Ip WK et al (2010) Serum levels of IL-33 and soluble ST2 and their association with disease activity in systemic lupus erythematosus. Rheumatology (Oxford) 49(3):520–527CrossRefGoogle Scholar
  28. 28.
    Miller AM (2011) Role of IL-33 in inflammation and disease. J Inflamm (Lond) 8(1):22CrossRefGoogle Scholar
  29. 29.
    Sugita S, Kawazoe Y, Imai A, Kawaguchi T, Horie S, Keino H, Takahashi M, Mochizuki M (2013) Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet’s disease. J Immunol. 190(11):5799–5808CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Wood IS, Wang B, Trayhurn P (2009) IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun 384(1):105–109CrossRefPubMedGoogle Scholar
  31. 31.
    Hudson CA, Christophi GP, Gruber RC, Wilmore JR, Lawrence DA, Massa PT (2008) Induction of IL-33 expression and activity in central nervous system glia. J Leukoc Biol 84(3):631–643CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Meephansan J, Komine M, Tsuda H, Karakawa M, Tominaga S, Ohtsuki M (2013) Expression of IL-33 in the epidermis: the mechanism of induction by IL-17. J Dermatol Sci 71(2):107–114CrossRefPubMedGoogle Scholar
  33. 33.
    Neely GG, Epelman S, Ma LL et al (2004) Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling. J Immunol 172(7):4225–4234CrossRefPubMedGoogle Scholar
  34. 34.
    Ali S, Mohs A, Thomas M, Klare J, Ross R, Schmitz ML, Martin MU (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-κB to dampen NF-κB-stimulated gene transcription. J Immunol 187(4):1609–1616CrossRefPubMedGoogle Scholar
  35. 35.
    Küchler AM, Pollheimer J, Balogh J et al (2008) Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol 173(4):1229–1242CrossRefPubMedCentralPubMedGoogle Scholar
  36. 36.
    Hot A, Lavocat F, Lenief V, Miossec P (2013) Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-α on endothelial cells. Ann Rheum Dis 72(5):754–760CrossRefPubMedGoogle Scholar
  37. 37.
    Gül A, Inanç M, Ocal L, Aral O, Koniçe M (2000) Familial aggregation of Behçet’s disease in Turkey. Ann Rheum Dis 59(8):622–625CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A (2009) HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum 61(10):1287–1296CrossRefPubMedGoogle Scholar
  39. 39.
    Remmers EF, Cosan F, Kirino Y et al (2010) Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet 42(8):698–702CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Mizuki N, Meguro A, Ota M et al (2010) Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet 42(8):703–706CrossRefPubMedGoogle Scholar
  41. 41.
    Htoon J, Nadig A, Hughes T, Yavuz S, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH (2011) IL18 polymorphism is associated with Behçet’s disease but not lupus in patients from Turkey. J Rheumatol 38(5):962–963CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Li C, Mu R, Guo J, Wu X, Tu X, Liu X, Hu F, Guo S, Zhu J, Xu H, Li Z (2014) Genetic variant in IL33 is associated with susceptibility to rheumatoid arthritis. Arthritis Res Ther 16(2):R105CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Suleyman Serdar Koca
    • 1
    Email author
  • Murat Kara
    • 2
  • Firat Deniz
    • 3
  • Metin Ozgen
    • 4
  • Caner Feyzi Demir
    • 5
  • Nevin Ilhan
    • 6
  • Ahmet Isik
    • 1
  1. 1.Department of Rheumatology, Faculty of MedicineFirat UniversityElazigTurkey
  2. 2.Department of Medical Genetics, Faculty of MedicineMugla Sitki Kocman UniversityMuglaTurkey
  3. 3.Department of Internal Medicine, Faculty of MedicineFirat UniversityElazigTurkey
  4. 4.Department of Rheumatology, Faculty of Medicine19 Mayis UniversityMalatyaTurkey
  5. 5.Department of Neurology, Faculty of MedicineFirat UniversityElazigTurkey
  6. 6.Department of Biochemistry, Faculty of MedicineFirat UniversityElazigTurkey

Personalised recommendations